SEOUL, South Korea, April 17, 2018 /PRNewswire/ — Seegene Inc. (096530.KQ), a leading developer of multiplex PCR technologies, announced that it will attend the 28th European Congress of Clinical Microbiology and Infectious Diseases (“ECCMID 2018”) taking place in Madrid, Spain, from April 21 to 24, 2018, where it will introduce the “combination test,” which is a high-efficiency solution that diagnoses... Read more
Seoul, South Korea – Jan 3, 2018 – Seegene Inc. (096530.KQ), a leading developer of multiplex PCR technologies headquartered in South Korea, announced today that, utilizing a newly created artificial intelligence (“AI”) based assay development system, the company succeeded in developing molecular diagnostics (“MDx”) assays in only four (4) days. These assays are high multiplex... Read more
Seoul, Korea, 2017/09/26 – Seegene, a world’s leading developer of multiplex molecular technologies and assays, announced that it has signed a Memorandum of Understanding (MOU) with Hamilton Company, a global leader in the design and manufacture of precision measurement devices, automated liquid handling workstations, and sample management systems. Through this strategic agreement, Seegene and Hamilton... Read more
2017.08.31 Seoul, Korea, 2017/08/31 – Seegene, the world’s leading developer of multiplex molecular technologies and assays, announced that it has recently signed collaborative contracts with 30 general hospitals and reference laboratories across 15 nations for the co-development of ‘Project 100’ products. Contracting parties are mostly the largest commercial labs in the country, university hospitals, and... Read more
Seoul, South Korea – July 26, 2017 – Seegene Inc. (096530.KQ), the world’s leading developer of multiplex molecular diagnostics technologies and assays, is to present its unique Seegene Random Access System (the “System”) at the 69th AACC Annual Clinical Lab Expo in San Diego, CA, from July 30 to August 3. The ‘Seegene Random Access... Read more
MOU signed between Mexico SAGARPA’s INIFAP and Seegene for collaborative product development and clinical study: (from middle to left) INIFAP’s bovine TB Director Dr. Ferando Otero, Head of Seegene Institute of Life Sciences Dr. Nackmoon … SEOUL, South Korea, June 21, 2017 /PRNewswire/ — Seegene Inc. (096530.KQ), a leading developer of multiplex PCR technologies headquartered... Read more
PR Newswire 2017.05.22 Seoul, Korea, 2017/05/22 – Seegene Inc. (096530.KQ), the world’s leading developer of multiplex molecular diagnostics technologies and assays, today announced that it has entered into a new strategic collaboration relationship with Thermo Fisher Scientific in which Seegene will file for U.S Food and Drug Administration (FDA) clearance of its AllplexTM diagnostic assay... Read more
26 Apr, 2017, 09:00 ET SEOUL, South Korea, April 26, 2017 /PRNewswire/ — Seegene Inc. (096530.KQ), the leading developer of multiplex PCR technologies, announced that it is entering into more innovative and powerful business realm by developing the Second-generation Real-time PCR Technology which has been recently patented in the United States and Europe. Seegene’s Second-generation... Read more
14 Feb, 2017, 09:00 ET SEOUL, South Korea, Feb. 14, 2017 /PRNewswire/ — Seegene Inc. (096530.KQ), a leading developer of multiplex PCR technologies today announced that it has developed a new software technology that can normalize test results of real-time PCR molecular diagnosis systems. This new innovative technology calibrates test results by correcting signal variations... Read more